These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37194136)

  • 21. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
    J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can
    Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
    J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L; McBean R; Yaxley J; Wong D
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C; McBean R; Parsons R; Wong D
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
    Meijer D; Luiting HB; van Leeuwen PJ; Remmers S; Jansen BHE; Bodar YJL; Witteveen T; Schaake EE; van der Poel HG; Wondergem M; Busstra MB; Nieuwenhuijzen JA; Meijnen P; Brabander T; van Moorselaar RJA; Hendrikse NH; Oprea-Lager DE; Roobol MJ; Vis AN
    J Urol; 2021 Apr; 205(4):1100-1109. PubMed ID: 33207138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: 'Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    Guercio A; Franco G; Lombardo R; De Nunzio C
    BJU Int; 2024 Apr; 133 Suppl 4():23-24. PubMed ID: 38098312
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma.
    Hoffmann MA; Buchholz HG; Wieler HJ; Müller-Hübenthal J; Trampert L; Richardsen I; Schreckenberger M
    Health Phys; 2020 Jul; 119(1):141-147. PubMed ID: 32301863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of PET-CT Imaging in Prostate Cancer.
    Subesinghe M; Kulkarni M; Cook GJ
    Semin Ultrasound CT MR; 2020 Aug; 41(4):373-391. PubMed ID: 32620228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    Rajarubendra N; Almeida F; Manojlovic Z; Ohe C; Ahmadi N; Cacciamani G; Qiu M; Abreu A; Cai J; Miranda G; Stern MC; Carpten J; Kuhn P; Amin MB; Gill PS; Aron M; Gill IS
    J Urol; 2019 Feb; 201(2):332-341. PubMed ID: 30218760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Ga
    Tarr GP; Kashyap P; Dixit DD; Willams AK; Koya MP; Lim R
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):78-86. PubMed ID: 31885207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on
    Markowski MC; Sedhom R; Fu W; Gray JCR; Eisenberger MA; Pomper MG; Pienta KJ; Gorin MA; Rowe SP
    J Urol; 2020 Sep; 204(3):496-502. PubMed ID: 32250727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ; Lee SW; Ha HK
    Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
    Gültekin A; Yaylalı O; Şengöz T; Yüksel D; Şahin B
    Nucl Med Commun; 2019 Dec; 40(12):1250-1255. PubMed ID: 31584465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
    Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU
    Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.